EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Management of Atrial Fibrillation With Tachycardia–Bradycardia Syndrome

Yulan Liu iD, Zhenjiang Liu iD

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/5618773 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 20.11.2026. Verfasst von Yulan Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China, csu.edu.cn. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Heart Rate, Bradycardia. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Medical Technology Innovation Guidance Project of the Hunan Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tachycardia–bradycardia syndrome (TBS), characterized by prolonged sinus pauses following termination of supraventricular tachyarrhythmias (predominantly atrial fibrillation), presents two primary curative strategies: catheter ablation (CA) and pacemaker implantation (PMI). Current guidelines (2024 ESC) recommend CA as a Class IIa intervention to improve symptoms and avoid PMI. Nevertheless, a significant proportion of patients (7.4%–22.4%) still require PMI after CA, primarily due to underlying intrinsic sinus node dysfunction (SND). Several predictors of PMI after CA have been reported, including preprocedural bradycardia‐related symptoms, prolonged corrected sinus node recovery time (cSNRT > 550 ms), longer posttachycardia pauses (> 6.3 s), daytime occurrence of the longest sinus pause, autonomic markers such as heart rate variability (HRV), right atrial remodeling reflected by an increased right‐to‐left atrial volume index ratio (RAVI/LAVI ratio > 0.812), elevated E/Em, atrial or perinodal fibrosis, atrioventricular conduction disease, and procedure‐related sinus node artery injury. Most proposed thresholds were derived from retrospective or single‐center cohorts and require prospective external validation. This review summarizes current evidence regarding the bidirectional interaction between atrial fibrillation (AF) and SND, distinguishes potentially reversible AF‐mediated or vagally mediated SND from intrinsic SND, and proposes a practical treatment‐oriented risk stratification framework. This framework classifies patients into three phenotypes: those likely to improve with CA alone, those at high risk of requiring PMI after CA, and those with vagally mediated functional SND who may be candidates for cardioneuroablation (CNA). Emerging strategies, including CNA, conduction system pacing (CSP), leadless pacemakers (LPMs), and biological pacemakers, may further refine individualized management. Future prospective multicenter studies are needed to validate integrated predictive models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationHeart RateBradycardiaCardiac Pacing, ArtificialTachycardia, SupraventricularAnti-Arrhythmia AgentsHumansTreatment OutcomeRisk FactorsPacemaker, ArtificialSyndromeSick Sinus SyndromeAction Potentials

Stichwörter der Autor:innen

cardioneuroablationcatheter ablationconduction system pacingpacemaker implantationprediction modelsinus node dysfunctiontachycardia–bradycardia syndrome

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China, csu.edu.cn.

ORCID-Profile: Yulan Liu, Zhenjiang Liu

Förderung

  • Clinical Medical Technology Innovation Guidance Project of the Hunan Provincial Department of Science and Technology

Zitieren

APA

Liu, Y., & Liu, Z. (2026). Advances in Management of Atrial Fibrillation With Tachycardia–Bradycardia Syndrome. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/5618773

Vancouver

Liu Y, Liu Z. Advances in Management of Atrial Fibrillation With Tachycardia–Bradycardia Syndrome. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/5618773

BibTeX
@article{Liu2026,
  author = {Liu, Yulan and Liu, Zhenjiang},
  title = {Advances in Management of Atrial Fibrillation With Tachycardia–Bradycardia Syndrome},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/5618773}
}
Kostenlos starten →